Hospitals Told to Pull Blood Thinner Argatroban Over Contamination Risk

Par Health USA has issued a voluntary nationwide recall of 22 lots of the blood-thinning drug argatroban after finding particulate contamination in some vials, the company announced this week in a notice posted to the Food and Drug Administration's website. The recall reaches hospitals and wholesalers rather than retail pharmacies, since the drug is administered intravenously in clinical settings.

What happened

The recalled product, Argatroban Injection 250 mg/2.5 mL, is a direct thrombin inhibitor used to prevent or treat blood clots in adults with heparin-induced thrombocytopenia, a dangerous immune reaction to the blood thinner heparin, and as an anticoagulant alternative for those same patients during cardiac stent procedures. According to the FDA's recall notice, testing identified particulate matter in certain lots consisting of cellulose, polystyrene, polyethylene terephthalate, stopper material and possibly stainless steel. Because the drug is injected directly into the bloodstream, the agency said administering contaminated product carries "a reasonable probability of causing life-threatening adverse health consequences," including pulmonary embolism, blockages in other blood vessels that can cause tissue death, and inflammation of vein walls that can lead to further clotting.

Par Health said it has not received any reports of injury or illness linked to the affected lots so far.

The numbers

The recall covers 22 lots across two package sizes, with expiration dates ranging from this month through September 2027, and reaches product distributed nationwide to wholesalers and hospitals between December 2024 and May 2026 — a shipping window of roughly a year and a half. The company's announcement says affected vials were labeled under two earlier company names, Par Pharmaceutical and Endo USA, both predecessor brands to Par Health USA, which the notice identifies as the product's current distributor. Returns are being handled through the recall-logistics firm Inmar.

How we got here

The argatroban recall is the latest in a string of quality issues traced to the same Rochester, Michigan facility this year. Federal recall records show Par Health recalled lots of buprenorphine hydrochloride injection in March for crystallization of the drug's active ingredient, expanded that recall to additional lots in June, and opened a third buprenorphine recall in September covering more than 150,000 bottles, also for crystallization. All three of those recalls are listed in the FDA's enforcement database as Class II actions, meaning the agency determined the defect could cause temporary or reversible health effects. The argatroban recall itself has not yet been assigned a formal classification, which the FDA typically does in the weeks following a company's announcement.

Par Health USA is a relatively new corporate name in the generic sterile-injectables business, tracing back to Endo International's generics division; the FDA notice itself states that "Par Pharmaceutical, Inc. and Endo USA, Inc. are predecessor companies to Par Health USA, LLC, the current distributor of the product." That lineage explains why hospitals may find the recalled vials labeled under either of the two older brand names even though the current recall notice is issued under the newer corporate identity.

Who's affected

The immediate burden falls on hospital pharmacies and wholesale distributors, who are being told to quarantine any affected stock and arrange returns rather than continue dispensing it. Because this is a hospital-level recall rather than one involving a drug sold directly to consumers, patients are not being asked to check their own medicine cabinets. Those currently receiving argatroban, or scheduled for a cardiac catheterization procedure where it might be used, may want to ask their care team whether their facility's supply is affected, since heparin-induced thrombocytopenia patients often have few alternative anticoagulant options.

Heparin-induced thrombocytopenia itself is an uncommon but serious complication in which a patient's immune system reacts against heparin, a blood thinner used routinely during surgery and in intensive care, triggering a dangerous drop in platelets alongside an elevated risk of clotting rather than bleeding. Because the condition rules out further use of heparin, clinicians rely on a short list of alternative anticoagulants, of which argatroban is among the most widely stocked, making hospital-level supply disruptions from a recall more consequential than they might be for a drug with more substitutes readily on hand.

Reaction

Clinical outlets covering the recall have emphasized the drug's narrow but important role: argatroban is one of a small number of approved alternatives for patients who cannot safely receive heparin, including some undergoing angioplasty or stent placement in the cath lab, which is why hospitals are being urged to act quickly on quarantining affected lots rather than simply waiting for a formal hazard classification.

Administering product affected by this issue "has a reasonable probability of causing life-threatening adverse health consequences," the FDA's recall notice states, citing the risk of pulmonary embolism and vessel blockage from injected particulate matter.

What happens next

The FDA has not yet classified the severity of the argatroban recall on its recalls index, and the agency's review process will determine whether it is treated as a Class I, II or III action; based on the timeline of Par Health's three earlier 2026 recalls, a classification could take several weeks. No injuries have been reported to date. Hospitals and distributors that received shipments between December 2024 and May 2026 are being contacted directly about returns, and any facility that further distributed the affected lots is required to notify its own downstream accounts. Health care providers who suspect an adverse reaction tied to the affected lots are directed to report it to the FDA's MedWatch program, the agency's standing channel for drug-safety complaints, in addition to notifying Par Health directly.

Taken together with the three buprenorphine recalls already on the books this year from the same Rochester plant, the argatroban recall adds to a pattern regulators and hospital pharmacists are likely to keep watching: four manufacturing-quality actions from a single sterile-injectables facility within roughly seven months, even as the company maintains that each issue was caught and addressed before any confirmed patient harm.